Recent research into HER2-targeted therapies, such as trastuzumab, has extended beyond breast cancer, showing potential benefits in other solid tumors where HER2 alterations contribute to aggressive tumor behavior and poor prognosis [13]. This evidence concerns the gene ERBB2 and breast carcinoma.